Correction to: Leukemia 10.1038/s41375-020-0743-y, published online 14 February 2020
In this article, Figure 1 was incorrect.
The updated figure can be found below.
The original article has been corrected.
. 2024 Jan 10;38(2):469–472. doi: 10.1038/s41375-023-02133-2
Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
Georg Lenz
1,✉, Eliza Hawkes
2, Gregor Verhoef
3, Corinne Haioun
4, Soon Thye Lim
5, Dae Seog Heo
6, Kirit Ardeshna
7, Geoffrey Chong
8, Jacob Haaber
9, Wei Shi
10, Igor Gorbatchevsky
11, Susanne Lippert
12, Florian Hiemeyer
12, Paolo Piraino
12, Georg Beckmann
12, Carol Peña
11, Viktoriya Buvaylo
11, Barrett H Childs
11, Gilles Salles
13
Georg Lenz
1Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany
Find articles by Georg Lenz
Eliza Hawkes
2Eastern Health Clinical School, Monash University, Olivia Newton John Cancer Research and Wellness Centre, Melbourne, VIC Australia
Find articles by Eliza Hawkes
Corinne Haioun
4Lymphoid Malignancies Unit, Groupe Hospitalier Henri Mondor-Albert Chenevier, Creteil, France
Find articles by Corinne Haioun
Soon Thye Lim
5National Cancer Centre Singapore and Duke-NUS Medical School, Singapore, Singapore
Find articles by Soon Thye Lim
Dae Seog Heo
6Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Find articles by Dae Seog Heo
Kirit Ardeshna
7University College London Hospitals NHS Foundation Trust, London, UK
Find articles by Kirit Ardeshna
Geoffrey Chong
8Ballarat Regional Integrated Cancer Centre, Ballarat, VIC Australia
Find articles by Geoffrey Chong
Jacob Haaber
9Department of Hematology, Odense University Hospital, Odense, Denmark
Find articles by Jacob Haaber
Igor Gorbatchevsky
11Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ USA
Find articles by Igor Gorbatchevsky
Susanne Lippert
12Pharmaceuticals Division, Bayer AG, Berlin, Germany
Find articles by Susanne Lippert
Florian Hiemeyer
12Pharmaceuticals Division, Bayer AG, Berlin, Germany
Find articles by Florian Hiemeyer
Georg Beckmann
12Pharmaceuticals Division, Bayer AG, Berlin, Germany
Find articles by Georg Beckmann
Viktoriya Buvaylo
11Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ USA
Find articles by Viktoriya Buvaylo
Barrett H Childs
11Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ USA
Find articles by Barrett H Childs
Gilles Salles
13Hospices Civils de Lyon, Université de Lyon, Centre Hospitalier Lyon-Sud, Service d’hématologie, Lyon, France
Find articles by Gilles Salles
1Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany
2Eastern Health Clinical School, Monash University, Olivia Newton John Cancer Research and Wellness Centre, Melbourne, VIC Australia
3University Hospitals Leuven, Leuven, Belgium
4Lymphoid Malignancies Unit, Groupe Hospitalier Henri Mondor-Albert Chenevier, Creteil, France
5National Cancer Centre Singapore and Duke-NUS Medical School, Singapore, Singapore
6Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
7University College London Hospitals NHS Foundation Trust, London, UK
8Ballarat Regional Integrated Cancer Centre, Ballarat, VIC Australia
9Department of Hematology, Odense University Hospital, Odense, Denmark
10Bayer China, Beijing, China
11Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ USA
12Pharmaceuticals Division, Bayer AG, Berlin, Germany
13Hospices Civils de Lyon, Université de Lyon, Centre Hospitalier Lyon-Sud, Service d’hématologie, Lyon, France
✉
Corresponding author.
Issue date 2024.
Subject terms: B-cell lymphoma, Targeted therapies
© The Author(s) 2024
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
PMCID: PMC10844080 PMID: 38200221
This corrects the article "Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma" in volume 34 on page 2184.